Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow RXRX
Recursion Pharmaceuticals, Inc. (RXRX) EV/Sales
As of 16 October 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at a EV/Sales of 23.7×. Over the past ten years it has ranged from 7.1× (March 2026) to 576× (July 2021); the current reading is higher than 32% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.6× | (32.55%) |
| FY2024 | 21.7× | (41.72%) |
| FY2023 | 37.2× | 91.29% |
| FY2022 | 19.4× | (92.15%) |
| FY2022 | 248× | 6.40% |
| FY2021 | 233× | 193.76% |
| FY2021 | 79.2× | 0.00% |
| FY2020 | 79.2× | 0.00% |
| FY2020 | 79.2× | 0.00% |
| FY2019 | 79.2× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 25.7× | 75.31% |
| Mar 2026 | 14.6× | 0.14% |
| Dec 2025 | 14.6× | (58.26%) |
| Sep 2025 | 35.0× | 41.60% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)